RHINOCORT Drug Patent Profile

When do Rhinocort patents expire, and what generic alternatives are available?

Rhinocort is a drug marketed by Astrazeneca and Kenvue Brands and is included in two NDAs.

The generic ingredient in RHINOCORT is budesonide. There is one drug master file entry for this compound. Forty suppliers are listed for this compound. Additional details are available on the budesonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rhinocort

A generic version of RHINOCORT was approved as budesonide by TEVA PHARMS on November 18^th, 2008.

Summary for RHINOCORT

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	13
DailyMed Link:	RHINOCORT at DailyMed

Recent Clinical Trials for RHINOCORT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medstar Health Research Institute	Phase 4
University of Wisconsin, Madison	Phase 4
Penn State College of Medicine	Phase 4

See all RHINOCORT clinical trials

US Patents and Regulatory Information for RHINOCORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	RHINOCORT	budesonide	AEROSOL, METERED;NASAL	020233-001	Feb 14, 1994		DISCN	No	No
Kenvue Brands	RHINOCORT ALLERGY	budesonide	SPRAY, METERED;NASAL	020746-003	Mar 23, 2015		OTC	Yes	Yes

EU/EMA Drug Approvals for RHINOCORT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Dr. Falk Pharma GmbH	Jorveza	budesonide	EMEA/H/C/004655Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age).	Authorised	no	no	yes	2018-01-08
Stada Arzneimittel AG	Kinpeygo	budesonide	EMEA/H/C/005653Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.	Authorised	no	no	yes	2022-07-15

RHINOCORT Market Dynamics, Patent Position, and Financial Trajectory

Last updated: September 27, 2026

Rhinocort is a mature intranasal corticosteroid franchise based on budesonide. Its U.S. prescription product, Rhinocort Aqua, lost meaningful exclusivity years ago, while Rhinocort Allergy competes in the over-the-counter allergy market against Flonase, Nasacort, generic budesonide, and store brands. The commercial model has shifted from prescription innovation to brand maintenance, retail distribution, price management, and seasonal demand capture.

Standalone Rhinocort revenue is not separately disclosed by AstraZeneca or other publicly reporting companies. The product is economically relevant as a durable consumer-health brand but is not a material disclosed driver of AstraZeneca’s current pharmaceutical revenue.

What is Rhinocort and how does it generate revenue?

Rhinocort contains budesonide, a locally acting glucocorticoid used to treat allergic rhinitis. It is administered as a nasal spray and reduces nasal congestion, sneezing, itching, and rhinorrhea.

Product	Active ingredient	Primary market	Regulatory status
Rhinocort Aqua	Budesonide	Prescription, historically	FDA-approved nasal spray
Rhinocort Allergy	Budesonide	U.S. OTC allergy market	FDA-approved switch from prescription to OTC
Generic budesonide nasal spray	Budesonide	Prescription and pharmacy retail	Multiple generic competitors
Brand equivalents outside the U.S.	Budesonide	Country-specific	Varies by jurisdiction

The product’s revenue sources are:

• Retail sales of Rhinocort Allergy.
• Prescription sales in countries where budesonide nasal spray remains branded or semi-branded.
• Licensing, distribution, or private-label arrangements.
• Seasonal allergy demand, which creates a pronounced spring and early-summer sales cycle.

The U.S. OTC product is sold under the Rhinocort Allergy name. AstraZeneca’s original prescription product was approved under NDA 20-746. The FDA approved the OTC switch for budesonide nasal spray in 2015, moving the franchise into direct consumer marketing and mass retail distribution.[1]

What is the FDA regulatory status of Rhinocort?

Rhinocort is an FDA-approved budesonide nasal spray with both prescription and OTC regulatory history.

Prescription approval

Rhinocort Aqua received FDA approval for the treatment of seasonal and perennial allergic rhinitis. Its prescription labeling established the clinical and dosing profile later used for the OTC product.[1]

OTC switch

The FDA approved Rhinocort Allergy for nonprescription use in 2015. The switch allowed consumers to self-select treatment for nasal allergy symptoms without a prescription. The product is marketed for adults and children aged six years and older, subject to label directions and age-related dosing instructions.[2]

The switch created a commercial reset:

1. Access expanded from physicians and pharmacies to supermarkets, mass merchants, warehouse clubs, and e-commerce.
2. Consumer advertising became more important than physician detailing.
3. Price comparisons intensified because shoppers could compare multiple intranasal steroids on the same shelf.
4. Generic and private-label products gained a more direct route to consumers.

Rhinocort remains a drug product rather than a simple cosmetic or wellness product. Manufacturing, labeling, pharmacovigilance, and advertising remain subject to FDA requirements.

When did Rhinocort lose exclusivity?

Rhinocort’s core pharmaceutical exclusivity has expired. The product does not depend on a currently protected budesonide molecule patent in the United States.

Exclusivity element	Rhinocort position
Active ingredient	Budesonide is an established, off-patent corticosteroid
Prescription product	Long past original regulatory and patent exclusivity
OTC switch	Regulatory status changed in 2015 but did not recreate molecule exclusivity
Formulation protection	Any historical protection is expired or commercially weak
Current competitive barrier	Brand recognition, retail placement, consumer trust, and manufacturing scale

The 2015 OTC switch was a regulatory expansion, not a new period of pharmaceutical exclusivity. FDA approval of an OTC version did not prevent generic budesonide nasal sprays from competing in the prescription market or prevent other intranasal corticosteroids from competing in retail channels.

What patents protect Rhinocort?

No currently material, unexpired U.S. patent estate is publicly associated with Rhinocort’s active ingredient or basic nasal-spray technology.

Historical patent position

Budesonide was developed decades ago, and the foundational compound and early formulation rights have expired. Historical patent protection may have covered:

• Budesonide composition and stereochemical characteristics.
• Aqueous nasal formulations.
• Metered-dose delivery systems.
• Suspension stability.
• Container and actuator configurations.
• Manufacturing processes.

Those rights no longer create a meaningful barrier to generic budesonide nasal spray development.

Current protection

The remaining commercial protections are primarily non-patent rights:

• Rhinocort and Rhinocort Allergy trademarks.
• Product labeling and brand recognition.
• Retailer relationships.
• Consumer advertising.
• Manufacturing know-how.
• Supply-chain scale and seasonal inventory planning.

This is a weak pharmaceutical patent estate but a potentially durable consumer brand position.

How many patents cover Rhinocort in the Orange Book?

Rhinocort’s current Orange Book position is not comparable to a recently launched branded drug with multiple active formulation and method-of-use patents. No material unexpired patent barrier is expected to prevent generic budesonide nasal spray competition.

Orange Book relevance is also reduced by the product’s OTC status. The key commercial issue is no longer whether a generic can enter after a Paragraph IV challenge. It is whether consumers will pay a premium for Rhinocort over generic budesonide, fluticasone, triamcinolone, or store-brand products.

Paragraph IV challenges

Paragraph IV litigation is not the principal current risk for Rhinocort. The principal loss-of-exclusivity event occurred before the present OTC market structure developed. Generic budesonide nasal sprays have been available, and any new entrant would generally face an established off-patent product rather than a protected innovator product.

No publicly material, ongoing Paragraph IV dispute involving a core Rhinocort patent is evident in the principal FDA and court-record framework through 2024.

What formulations are protected by Rhinocort?

The commercially important formulation is an aqueous budesonide nasal suspension delivered through a metered spray pump.

The formulation value lies in performance rather than enforceable exclusivity:

Formulation attribute	Commercial impact
Aqueous suspension	Supports nasal delivery and consumer familiarity
Metered spray	Provides dose consistency and ease of use
Local corticosteroid delivery	Limits systemic exposure relative to oral corticosteroids
Multi-dose packaging	Supports recurring seasonal use
OTC labeling	Enables self-treatment without physician intervention

Formulation barriers remain practical rather than legal. A competitor must achieve acceptable suspension uniformity, dose delivery, microbial control, device performance, stability, packaging, and consumer usability. These requirements can delay launch or increase manufacturing costs, but they do not prevent competition when the underlying formulation patent rights have expired.

How strong is the Rhinocort patent estate?

Rhinocort has a low patent-strength rating and a moderate brand-strength rating.

Dimension	Assessment	Rationale
Molecule patent protection	Weak	Budesonide is long off patent
Formulation patents	Weak	Historical rights are expired or have limited remaining value
Method-of-use protection	Weak	Allergic-rhinitis use is established and broadly understood
Device protection	Weak to moderate	Delivery systems can be designed around
Trademark	Moderate to strong	Rhinocort is an established allergy brand
Manufacturing know-how	Moderate	Quality and supply reliability matter, but are replicable
Retail position	Moderate	Depends on distribution, advertising, and retailer support

The distinction between patent strength and brand strength is central to the product’s outlook. Rhinocort cannot rely on patent pricing. It must rely on consumer preference and channel execution.

Which companies compete with Rhinocort?

Rhinocort competes in a crowded intranasal allergy market.

Competitor	Active ingredient	Commercial positioning
Flonase	Fluticasone propionate or fluticasone furoate	Major OTC nasal-steroid brand
Nasacort	Triamcinolone acetonide	Established OTC nasal-steroid competitor
Generic budesonide	Budesonide	Lower-price therapeutic substitute
Generic fluticasone	Fluticasone	Broad pharmacy and retail availability
Generic triamcinolone	Triamcinolone	Price-led substitute
Nasonex/generic mometasone	Mometasone	Prescription and OTC-related competition depending on market
Antihistamine sprays	Azelastine and others	Alternative mechanism and symptom profile
Oral antihistamines	Cetirizine, loratadine, fexofenadine	Substitute allergy treatment

Flonase has generally held the strongest mass-market position among U.S. OTC nasal allergy brands. Rhinocort’s differentiation is based on budesonide’s long clinical history, brand recognition, and consumer perceptions around efficacy and tolerability rather than a novel mechanism.

How does Rhinocort compare with Flonase and Nasacort?

Factor	Rhinocort	Flonase	Nasacort
Active ingredient	Budesonide	Fluticasone	Triamcinolone
Market maturity	Mature	Mature	Mature
U.S. OTC status	Yes	Yes	Yes
Patent moat	Low	Low	Low
Brand competition	High	Very high	High
Generic substitution	High	High	High
Primary advantage	Established budesonide brand	Scale and consumer awareness	Established OTC positioning
Main weakness	Limited differentiation	Intense private-label competition	Limited differentiation

The products are therapeutically substitutable for many consumers, although individual response, dosing preference, tolerability, and device experience influence repeat purchases. Since all three brands compete in a low-innovation category, advertising, retailer placement, promotions, and price are more important than patent status.

What is the financial trajectory for Rhinocort?

Rhinocort’s financial trajectory is mature to declining on a per-unit basis, with potential stability in nominal sales if the brand maintains distribution and pricing.

AstraZeneca does not separately report Rhinocort revenue in its annual reports. The company reports major prescription products and therapeutic areas, while small or divested consumer products are generally aggregated or excluded from individual disclosure.[3] As a result, there is no reliable public standalone revenue series for Rhinocort.

Revenue trajectory

Period	Financial development
Pre-2015	Prescription-driven sales with physician and pharmacy access restrictions
2015 onward	OTC switch expanded distribution and consumer access
Post-switch maturity	Higher retail reach but stronger price competition
Current phase	Brand maintenance, seasonal demand, generic and private-label pressure

The OTC switch likely improved addressable-market access but did not create a durable pricing moat. Unit volume can remain healthy while net revenue declines because of:

• Retail promotions.
• Store-brand substitution.
• Generic pricing.
• E-commerce price transparency.
• Retailer bargaining power.
• Lower-cost competing steroid sprays.
• Marketing costs needed to defend brand awareness.

Rhinocort’s margin profile is likely better than that of a complex specialty drug because the active ingredient is established and the product is manufactured at scale. However, OTC consumer-health economics include retailer trade spending, advertising, packaging, returns, and seasonal inventory costs.

What revenue exposure does Rhinocort create for AstraZeneca?

Rhinocort is not a material disclosed revenue exposure for AstraZeneca compared with products such as Farxiga, Tagrisso, Symbicort, Fasenra, and Imfinzi.

The principal financial implications are:

• Limited upside from pharmaceutical innovation.
• Low exposure to patent-cliff litigation.
• Low exposure to biosimilar competition.
• Ongoing exposure to OTC pricing and retailer decisions.
• Potential value from brand licensing or divestiture.
• Limited impact on AstraZeneca’s consolidated earnings if the product declines.

A Rhinocort decline would be commercially relevant to the brand owner or licensee managing consumer-health sales, but it would not be expected to materially change AstraZeneca’s group-level financial trajectory.

Does Rhinocort face biosimilar risk?

No. Biosimilars apply to biological products, while Rhinocort contains budesonide, a chemically synthesized small molecule. Rhinocort faces generic and therapeutic substitution risk, not biosimilar risk.

The relevant competitors are:

• Generic budesonide nasal sprays.
• Generic fluticasone and triamcinolone.
• Branded OTC nasal steroids.
• Oral antihistamines.
• Antihistamine nasal sprays.
• Non-drug allergy interventions.

What generic launch scenarios exist for Rhinocort?

The most likely scenarios are commercial rather than litigation-driven.

Scenario 1: Continued brand erosion

Generic and private-label products gain share, forcing Rhinocort to increase promotions or reduce price. This produces gradual revenue and margin erosion.

Scenario 2: Stable premium brand

Rhinocort retains a stable consumer segment that values the brand, perceived efficacy, or prior experience. Unit volume declines modestly, but pricing and distribution preserve a meaningful revenue base.

Scenario 3: Retailer-led substitution

Large retailers emphasize store-brand budesonide or competing intranasal steroids. Shelf space and search placement shift away from Rhinocort, accelerating volume loss.

Scenario 4: Portfolio monetization

The brand owner licenses or sells regional rights to a consumer-health company. The buyer may operate Rhinocort as a cash-generative niche brand with lower corporate overhead.

The most probable outcome is gradual erosion rather than a sudden patent-triggered collapse.

What patent litigation and settlement agreements affect Rhinocort?

No major current patent-litigation event appears to define the Rhinocort market. The product’s central legal risk is ordinary generic competition after expiration of foundational rights.

There is no widely reported settlement framework comparable to the settlements associated with high-value oncology, immunology, diabetes, or cardiovascular brands. Any private manufacturing, distribution, or trademark agreements would not necessarily be disclosed in public securities filings.

What geographic markets matter for Rhinocort?

The United States is the most important market for the OTC Rhinocort Allergy business because of its large self-care allergy category and extensive mass-retail distribution.

Outside the United States, the product’s commercial status varies:

• Some markets retain prescription distribution.
• Some markets use local licensees or distributors.
• Some markets sell budesonide under different brand names.
• Reimbursement rules can favor generic substitution.
• OTC switching requirements differ by country.

Geographic patent protection is not a major growth driver. The product’s relevant international assets are trademarks, registrations, supply agreements, and distribution rights rather than active composition patents.

What is the outlook for Rhinocort?

Rhinocort is a defensible mature brand, not a protected pharmaceutical platform. Its value depends on:

• Retail availability during peak allergy seasons.
• Consumer advertising efficiency.
• Competitive pricing.
• Product quality and spray performance.
• Retailer relationships.
• Digital search visibility.
• Continued consumer preference for branded treatment.
• Reliable manufacturing and inventory management.

The product can remain profitable despite weak patent protection because nasal allergy treatment is recurrent, the dosage form is familiar, and manufacturing complexity is manageable. The ceiling is limited by therapeutic interchangeability and aggressive generic pricing.

Key Takeaways

• Rhinocort contains budesonide and is used for allergic rhinitis.
• The U.S. product moved from prescription to OTC status in 2015.
• Core molecule and formulation exclusivity have expired.
• Rhinocort has no material current patent moat.
• Paragraph IV litigation is not the main competitive issue.
• Generic, private-label, Flonase, and Nasacort competition drive pricing pressure.
• Biosimilar risk is irrelevant because budesonide is a small molecule.
• AstraZeneca does not separately disclose Rhinocort revenue.
• The brand’s financial trajectory is mature, with gradual erosion risk rather than a sharp patent cliff.
• Commercial value rests on trademark, retail access, consumer loyalty, and supply execution.

FAQs

Is Rhinocort still protected by patents?

No material unexpired U.S. patent protection is expected to prevent competition with budesonide nasal spray. Rhinocort’s remaining protection is primarily trademark and brand-based.

Is Rhinocort stronger than Flonase?

Neither product has a material modern patent advantage. Clinical response varies by patient, while commercial strength depends on brand awareness, price, retail placement, and consumer advertising.

Can generic companies launch a Rhinocort equivalent?

Yes. Generic budesonide nasal sprays can compete where approved and marketed. The main barriers are FDA approval, manufacturing quality, distribution, and commercial scale.

Is Rhinocort an OTC or prescription drug?

Rhinocort Allergy is marketed over the counter in the United States. Rhinocort Aqua also has prescription regulatory history, and budesonide nasal spray may remain prescription-only or differently branded in other countries.

Is Rhinocort a significant AstraZeneca revenue product?

No. AstraZeneca does not separately report Rhinocort revenue, and the product is not comparable in financial scale with the company’s major oncology, respiratory, cardiovascular, or metabolic medicines.

References

1. U.S. Food and Drug Administration. (n.d.). Rhinocort Aqua budesonide nasal spray prescribing information. FDA Drugs@FDA database.

2. U.S. Food and Drug Administration. (2015). FDA approves first over-the-counter nasal spray to treat allergies. FDA.

3. AstraZeneca PLC. (2024). Annual report and Form 20-F 2023. AstraZeneca.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.